favicon-32x32.png

Pfizer 2021 Annual Report

Caregiver holding hands of patient, who is showing signs of muscle wasting

large_forging_new_pathways_to_treat_unintentional_weight_loss_hero.jpeg

medium_forging_new_pathways_to_treat_unintentional_weight_loss_hero.jpeg

small_forging_new_pathways_to_treat_unintentional_weight_loss_hero.jpeg

thumbnail_forging_new_pathways_to_treat_unintentional_weight_loss_hero.jpeg

forging_new_pathways_to_treat_unintentional_weight_loss_hero.jpeg

Forging New Pathways to Treat Unintentional Weight Loss

Patients living with certain chronic illnesses, such as cancer, congestive heart failure, or chronic obstructive pulmonary disease (COPD), often develop a serious metabolic condition called cachexia, which can cause unintentional weight loss, loss of appetite, muscle wasting, and/or fatigue.*^1,2,3* This wasting disorder can severely impact patients’ quality of life and, in some cases, hinder their ability to continue treatment for their primary illness.*^3*

For patients, the impact of cachexia on daily life is far-reaching. During a [Cancer Support Community patient-focused drug development meeting](https://www.cancersupportcommunity.org/cachexia-pfdd) we sponsored in 2021, patients described the emotional and physical impacts of losing their appetites and later their ability to handle daily living tasks, such as getting out of bed and taking a shower. Caregivers also shared the challenges of watching loved ones go through this transformation.

These real-life insights from people affected by cachexia are helping scientists determine how to address the disease in a meaningful way. With patient input, our efforts are aimed at tackling multiple symptoms at once, understanding that improving appetite and reversing muscle wasting both play a critical role in improving quality of life.

Our lead cachexia program focuses on a novel mechanism, growth differentiation factor-15 (GDF-15), a cellular signaling protein linked to appetite and energy regulation. Patients with late-stage illnesses, particularly cancer, have elevated levels of this signaling protein. It’s believed that GDF-15 interacts with receptors in the brain related to appetite control, causing loss of appetite and nausea.

In pre-clinical models, scientists have found that a GDF-15-blocking antibody could help restore appetite, improve body composition and promote weight gain in mice. While the research is still early, scientists hope these results could translate to cancer patients, who often need to limit their chemotherapy doses due to loss of body weight. “We’re either using one target with a lot of horsepower or multiple targets in combination that could treat multiple aspects of the disease,” said Danna Breen, Ph.D., an Associate Research Fellow in Pfizer’s Internal Medicine Research Unit.

large_forging_new_pathways_to_treat_unintentional_weight_loss_01.jpg

medium_forging_new_pathways_to_treat_unintentional_weight_loss_01.jpg

small_forging_new_pathways_to_treat_unintentional_weight_loss_01.jpg

thumbnail_forging_new_pathways_to_treat_unintentional_weight_loss_01.jpg

forging_new_pathways_to_treat_unintentional_weight_loss_01.jpg

Pfizer is currently conducting a Phase 1 study to better understand the safety, tolerability and pharmacological activity of an investigational GDF-15 antibody when administered to patients with cancer and cachexia.

Our scientists are also pursuing separate cachexia programs to combat other forms of anorexia and unintentional weight loss, which are designed to be complementary to the GDF-15 antibody. “Novel science is emerging to increase our understanding of how these pathways interact with one another,” said Breen. “Hopefully, this will lead us to identify the most effective therapies.”

With a patient-centered approach, researchers could potentially tailor cachexia treatment combinations based on patients’ needs. “We’re really hoping to improve patient quality of life,” added Breen.

Developing Potential Cancer Treatments to Cross the Blood-Brain Barrier

Woman wearing a headscarf smiling to camera

developing_potential_cancer_treatments_to_cross_the_blood_brain_barrier_hero.jpeg

Charting a New Course for a COVID-19 Treatment

Male clinician advising a female while seated next to each other

charting_a_new_course_for_a_covid_19_treatment_hero.jpeg

Myfembree® Brings New Hope to Women with Uterine Fibroids

Woman in a mask looking through a glass door

myfembree_brings_new_hope_to_women_with_uterine_fibroids_hero.jpeg

Abstract image of Pfizer labs/office space from a far away POV

large_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_hero.png

medium_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_hero.png

small_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_hero.png

thumbnail_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_hero.png

fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_hero.png

Fueling Tomorrow’s Breakthrough Therapies Through the Power of Data at Scale

Genomics – and single-cell ribonucleic acid sequencing (scRNAseq) in particular – continue to play an increasingly vital role in the discovery of novel drugs and vaccines. Sequencing RNA provides fundamental insights into the regulation of genomes. Interpreting large-scale, complex transcriptomics data is critically important to understanding the molecular and cellular basis of disease.

“Data analytics and insights, powered by artificial intelligence and machine learning, are key to speed and innovation,” says Lidia Fonseca, Chief Digital and Technology Officer, Pfizer.

Pfizer has been on the leading edge of innovation, leveraging large scale data and advanced technology platforms to fuel tomorrow’s breakthrough therapies.

Pfizer has developed a state-of-the-art supercomputing center that is being used by our scientists to accelerate our research and development efforts. Researchers have run large scale models and simulations to predict the structure of COVID-19 oral candidates, optimize mRNA manufacturing processes, improve storage stability of mRNA vaccine, and create scientific images and documents for U.S. Food and Drug Administration (FDA) filings.

large_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_01.jpg

medium_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_01.jpg

small_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_01.jpg

thumbnail_fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_01.jpg

fueling_tomorrows_breakthrough_therapies_through_the_power_of_data_at_scale_01.jpg

In addition, this year, Pfizer partnered with Seven Bridges, an industry-leading bioinformatics provider, to support the development of a scRNAseq data management and collaboration solution, which carries a very large data footprint. In combination with Pfizer’s cloud-based environment, research teams can analyze, compute and interpret large scale data sets to conduct bioinformatic analyses that support clinical discovery efforts.

This partnership underscores the growing importance of efficient genomic data management, visibility and retrieval. The agreement is introducing avenues to expand Pfizer’s cloud platforms and capabilities, a key component of Pfizer’s integrated digital cloud and advanced analytics strategy.

Pfizer’s evolving capabilities and partnerships are maximizing the value of our data and empowering Pfizer to accelerate the delivery of breakthroughs that change patients’ lives.

Applying the Latest Digital Technology to Optimize COVID-19 Vaccine Efforts

Male and female scientist looking at a computer screen together

applying_the_latest_digital_technology_to_optimize_covid_19_vaccine_efforts_hero.png

Improving Patient Health Outcomes with Digital Technology

improving_patient_health_outcomes_with_digital_technology_hero.jpeg

Digital Is Unleashing the Power of our People

Two male scientists filling vials in a lab

digital_is_unleashing_the_power_of_our_people_hero.png

Male scientist conducting research in a lab while female scientist looks on

medium_on_the_fast_track_to_a_more_targeted_treatment_for_rare_disease_hero.jpeg

small_on_the_fast_track_to_a_more_targeted_treatment_for_rare_disease_hero.jpeg

thumbnail_on_the_fast_track_to_a_more_targeted_treatment_for_rare_disease_hero.jpeg

on_the_fast_track_to_a_more_targeted_treatment_for_rare_disease_hero.jpeg

On the Fast Track to a More Targeted Treatment for Rare Disease

Wilson disease may be rare, but its impact can be substantial. Affecting approximately one in 30,000 people worldwide,*^1* Wilson disease is caused by a mutation on a single gene – ATP7B – leading to excessive and potentially life-threatening buildup of copper in the liver, brain, eyes, and other parts of the body. Current treatment options focus on clearing this copper buildup.*^2* While these treatments offer some benefit for patients, a more holistic approach is needed to address the condition. A new investigational gene therapy aims to address the underlying cause of Wilson disease and deliver a functioning copy of the gene to the liver, which may offer promise to patients and their families.

We are collaborating with Vivet Therapeutics, a French biotech company, to develop an investigational adeno-associated virus (AAV) gene therapy to treat Wilson disease. Vivet’s therapeutic candidate, known as VTX-801, recently received Fast Track designation from the U.S. Food and Drug Administration (FDA), a process designed to facilitate development and expedite the review of potential medicines that are being developed to treat serious conditions addressing an unmet need.*^3*

Black x-ray with blue outline that highlights liver

large_Image 1_On the Fast Track to a More Targeted Treatment for Rare Disease .jpg

medium_Image 1_On the Fast Track to a More Targeted Treatment for Rare Disease .jpg

small_Image 1_On the Fast Track to a More Targeted Treatment for Rare Disease .jpg

thumbnail_Image 1_On the Fast Track to a More Targeted Treatment for Rare Disease .jpg

on_the_fast_track_to_a_more_targeted_treatment_for_rare_disease_01.jpg

“The FDA’s decision to grant VTX-801 Fast Track designation underscores the urgent need for new therapeutic options to address this devastating disease which, if left untreated, can be fatal,” said Seng H. Cheng, Senior Vice President and Rare Disease Research Unit Chief Scientific Officer, at Pfizer.

Through this collaboration – which brings together the scientific expertise of both companies as well as our state-of-the art gene therapy manufacturing capabilities – Pfizer and Vivet hope to advance this potential therapy more rapidly for patients living with this rare, inherited liver disorder. VTX-801 is currently under investigation in a Phase 1/2 clinical trial, called GATEWAY, to determine its safety, tolerability, and durability.

“Wilson disease can be debilitating, difficult to diagnose, and complicated to manage,” Cheng said. “We believe in the promise of gene therapy to target the root cause of this disease and to make a meaningful difference in the lives of patients, utilizing a novel treatment approach.”

Delivering Dosing Options for Patients With a Rare Neurological Disease

Close-up of a physician holding hands with a patient

delivering_dosing_options_for_patients_with_rare_neurological_disease_hero.jpeg

Unlocking the Potential of mRNA for Flu

Pfizer scientist in a lab holding a bottle

unlocking_the_potential_of_mrna_for_flu_hero.jpeg

Bringing Vaccine Science to Tick-Borne Diseases

Male scientist in goggles and mask looking at a computer screen

bringing_vaccine_science_to_tick_borne_diseases_hero.jpeg

Vials containing doses of the Pfizer-BioNTech COVID-19 vaccine make their way through a production line

large_covid_19_vaccination_deepening_the_publics_trust_through_science_01.jpeg

medium_covid_19_vaccination_deepening_the_publics_trust_through_science_01.jpeg

small_covid_19_vaccination_deepening_the_publics_trust_through_science_01.jpeg

thumbnail_covid_19_vaccination_deepening_the_publics_trust_through_science_01.jpeg

covid_19_vaccination_deepening_the_publics_trust_through_science_hero.jpeg

COVID-19 Vaccination: Deepening the Public’s Trust Through Science

Immunization is the single most important public health advancement in history, after clean water.*^1* We are proud to have a rich legacy in vaccine research and development. For decades, we have played a pivotal role in helping to eliminate deadly infectious diseases like smallpox and polio globally. We’ve designed novel vaccines based on new delivery systems and technologies that have helped prevent bacterial infections. Now, with our collaboration partner, BioNTech, we’ve successfully developed a breakthrough vaccine against COVID-19 using mRNA, or messenger RNA.

While billions of people worldwide are vaccinated against COVID-19, some people remain vaccine-hesitant. Many factors influence vaccine decision-making, including cultural, social, political, and vaccine-specific factors. People may also want to know more about how COVID-19 vaccines were developed and authorized, as well as how we and health agencies established their safety profiles and effectiveness.*^2*

We remain committed to being transparent when it comes to sharing information of our ongoing COVID-19 vaccine trials. To date, we’ve published data on the safety and efficacy of the Pfizer-BioNTech COVID-19 vaccine from various global studies in leading peer-reviewed journals.

Additionally, real-world effectiveness data, including that from Israel, have continued to provide important information on the safety and effectiveness of our COVID-19 vaccine against infection and severe disease. Data from these real-world studies have helped shape local decision-making in numerous countries for regulatory approvals, vaccine schedules, and authorization of booster doses.

Altogether, we believe clinical and real-world data are critical to understanding the true value of vaccines in combatting this deadly disease. Looking ahead, we will continue to share data from our ongoing COVID-19 clinical studies and real-world analyses.

*Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at [www.cvdvaccine-us.com](https://www.cvdvaccine-us.com).*

Our Global Patients in Focus Week

Four colleagues and patient advocacy group leaders seated side by side on stage for Patients in Focus Week event

our_global_patients_in_focus_week_hero.jpg

Embedding DEI into Our Purpose

Members of Pfizer's Diversity, Equity and Inclusion team at hiring event

embedding_dei_into_our_purpose_hero.jpg

Building Our Next Generation of Leaders

Pfizer CEO Albert Bourla in a small-group Zoom session with the 2021 Breakthrough Fellows

building_our_next_generation_of_leaders_hero.jpg

Female scientist in goggles and a mask smiling to camera

large_expanding_colleague_health_and_wellness_support_with_new_resources_hero.jpeg

medium_expanding_colleague_health_and_wellness_support_with_new_resources_hero.jpeg

small_expanding_colleague_health_and_wellness_support_with_new_resources_hero.jpeg

thumbnail_expanding_colleague_health_and_wellness_support_with_new_resources_hero.jpeg

expanding_colleague_health_and_wellness_support_with_new_resources_hero.jpeg

Expanding Colleague Health and Wellness Support with New Resources

Healthy colleagues function at their best, and in turn, contribute to the scientific community and the health of our patients. We realize that for our colleagues to be their best, we must be committed to their health and wellness. That’s why, each year, we make new investments to help colleagues manage their mental and physical well-being.

In 2021, Pfizer partnered with Thrive Global to encourage and enable colleagues to take ownership of their mental health and wellness. We integrated tools and resources into the fabric of our company’s culture through leader-led forums, town halls, meetings, broadcasts, and the Pfizer Thrive app. Colleagues also received a “Wellness Day” — an extra paid day off from work to focus on health, well-being, and whatever brings them joy and relaxation.

small_thrive-global-logo.jpeg

thumbnail_thrive-global-logo.jpeg

expanding_colleague_health_and_wellness_support_with_new_resources_01.jpeg

At Pfizer, the importance of unleashing the power of our people means creating an environment where colleagues feel personally and professionally fulfilled, which will make us more successful than ever in delivering breakthrough medicines to patients. We are proud to partner with Thrive Global to create opportunities that empower colleagues to better care for themselves.

Showcasing our Scientists and Sites

Pfizer scientist standing alone in a long row of lab equipment

showcasing_our_scientists_and_sites_hero.png

‘Doing Our Part’: A Colleague’s COVID Vaccine Trial Experience

Family image of father and two small children

doing_our_part_a_colleagues_covid_vaccine_trial_experience_hero.jpg

large_bringing_vaccine_science_to_tick_borne_diseases_01.jpeg

medium_bringing_vaccine_science_to_tick_borne_diseases_01.jpeg

small_bringing_vaccine_science_to_tick_borne_diseases_01.jpeg

thumbnail_bringing_vaccine_science_to_tick_borne_diseases_01.jpeg

While the world, including Pfizer, has been focused on vaccines for COVID-19, we have not lost sight of the many other diseases that continue to affect people globally. In 2021, a key focus for us continued to be working to help prevent certain tick-borne diseases, which are increasingly prevalent across North America and Europe. As people’s interest in spending time outdoors in nature increases,*^1* whether on vacations or closer to home, helping to protect against diseases caused by certain ticks has become even more important.

Vaccination is available, in certain markets, to help protect people from some harmful diseases that can be a risk while spending time outdoors, such as tick-borne encephalitis (TBE).*^2* However, for Lyme disease, another prevalent tick-borne infection, there is currently no approved vaccine for humans.*^3* That’s something we’re aiming to change through one of our collaborations.

**Targeting Lyme disease with VLA15**

Lyme disease is an infection caused by Borrelia burgdorferi bacteria, which is transmitted to humans by infected Ixodes (deer) ticks.*^4* Despite a high number of infections, there are currently no available vaccines to help prevent Lyme disease,*^3* which is why we are committed to addressing this important public health need.

In April 2020, we announced a collaboration with Valneva,*^5* a specialist vaccine company focused on infectious diseases, to develop and commercialize a Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical trials. As of November 15, 2021, Pfizer assumed responsibility from Valneva for the Investigational New Drug Application (IND) for VLA15 with the U.S. Food and Drug Administration (FDA).

VLA15 is the only active Lyme disease vaccine candidate currently in clinical development. This investigational vaccine uses an established mechanism for Lyme disease vaccines, targeting the outer surface protein of B. burgdorferi. VLA15 was granted Fast Track designation by the FDA in July 2017,*^6* and has demonstrated strong immune system response and safety data in pre-clinical and clinical studies so far. “The prevalence and geographic reach of Lyme disease is growing, underscoring the major medical need for vaccination against the disease,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer. “We are proud to continue the development efforts in our quest to potentially protect people from Lyme disease in the future.” 

large_new_Tickborne-Disease_inline1.jpg

medium_new_Tickborne-Disease_inline1.jpg

small_new_Tickborne-Disease_inline1.jpg

thumbnail_new_Tickborne-Disease_inline1.jpg

bringing_vaccine_science_to_tick_borne_diseases_01.jpg

**TicoVac™ reaches a new milestone 45 years on**

Meanwhile, we continue to bring our tick-borne encephalitis (TBE) vaccine, TicoVac, to where it’s needed most.

TBE is a rare but serious viral infection of the brain and spine,*^7* most commonly transmitted to humans through the bite of an infected tick.*^2* It can be a serious condition with possible long-term consequences.*^7,8* To date, ticks infected with the TBE virus have been reported in more than 30 countries across Europe and in Japan.*^2*

There are a number of steps an individual can take to help protect themselves from TBE when in a risk area, such as applying effective insect repellent and wearing long-sleeved clothing.*^9* However, according to the World Health Organization, vaccination is considered the most effective prevention measure for TBE.*^10*

small_Image 2_Bringing Vaccine Science to Tick-Borne Diseases.jpg

thumbnail_Image 2_Bringing Vaccine Science to Tick-Borne Diseases.jpg

bringing_vaccine_science_to_tick_borne_diseases_02.jpg

In August 2021, 45 years after its first approval in Austria under the brand name FSME-Immun®, TicoVac was approved by the FDA for active immunization to prevent TBE in individuals one year of age and older.*^11* TicoVac is currently the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE-endemic areas. Many people may benefit from TicoVac, including military troops stationed abroad.

“This vaccine has helped to protect millions of people in TBE-endemic regions since its first approval outside the U.S. 45 years ago,” said Nanette Cocero, Ph.D., Global President of Pfizer Vaccines. “We are proud to deliver the first vaccine to help protect people in the U.S. against TBE if they are traveling to any risk areas, so they are able to spend time outdoors without worrying about the impact of this potentially serious disease.”

Generating New Data to Help Support Vaccination Adherence

HCP with dark curly hair and glasses talking with her elderly patient

generating_new_data_to_help_support_vaccination_adherence_hero.jpg

Pursuing Breakthroughs for People with Immuno-Inflammatory Conditions

Female clinician advising a female patient while seated at a desk

pursuing_breakthroughs_for_people_with_immuno_inflammatory_conditions_hero.jpeg

Plane dropping COVID-19 vaccines from zipline drone in Ghana

large_working_to_end_the_pandemic_for_people_all_over_the_world_01.jpg

medium_working_to_end_the_pandemic_for_people_all_over_the_world_01.jpg

small_working_to_end_the_pandemic_for_people_all_over_the_world_01.jpg

thumbnail_working_to_end_the_pandemic_for_people_all_over_the_world_01.jpg

working_to_end_the_pandemic_for_people_all_over_the_world_hero.jpg

Working to End the Pandemic For People All Over the World

Pfizer is actively working with governments and health partners around the world toward fair and equitable access to COVID-19 vaccines and treatments. We’re also providing expertise and resources to help strengthen health care systems that need greater support. To accelerate efforts to reach vulnerable populations, we have pledged to provide 2 billion doses of our COVID-19 vaccine to low- and middle-income countries in 2021 and 2022 – at least 1 billion doses each year.

Plane provides COVID-19 vaccines in Kigali, Rwanda

working_to_end_the_pandemic_for_people_all_over_the_world_01.jpg

To do this, we have established direct supply agreements with country governments and supply agreements with supranational organizations like the World Health Organization-led COVAX Facility as well as partnerships with wealthy nations to provide doses to countries in need and humanitarian donations to reach refugee populations.

In 2021, Pfizer and BioNTech reached an agreement with the U.S. government (USG) to provide one billion doses of our COVID-19 vaccine at the not-for-profit price — 200 million doses in 2021 and 800 million in 2022. The U.S. government is donating these doses to Africa and to the 92 COVAX Advanced Market Commitment (AMC) low- and lower-middle- income countries. The first USG-donated shipment reached Rwanda on August 18, 2021, and, since then, we have worked closely with the U.S. government, the COVAX Facility and country governments to supply doses to populations in need, reaching nearly 80 countries in just the first four months of the initiative.

In addition to the USG program, we have worked closely with the European Union to coordinate their donation of vaccine doses from excess supply to countries in need.

Infographic showing Pfizer Pledge of 2 billion doses to low- and middle-income countries over 2 years and 1 billion doses achieved in 2021

working_to_end_the_pandemic_for_people_all_over_the_world_02.svg

To reach vulnerable refugee populations as part of a collaboration with the Jordanian Ministry of Health and United Nations High Commissioner for Refugees (UNHCR), Pfizer and BioNTech donated 200,000 vaccine doses to the country to replace the doses Jordan had administered to refugees from its national supply. This donation is intended to help Jordan to effectively and efficiently manage a national vaccination program to reach its entire population while ensuring that additional support is provided to protect the most vulnerable. Additionally, as part of the companies’ collaboration with Lebanon’s Ministry of Health and UNHCR, Pfizer and BioNTech will also donate up to 600,000 vaccine doses to Lebanon to replace doses administered from its national supply. The first shipment with 100,000 doses reached Lebanon in September 2021. The remaining doses will be delivered when requested by the country.

Infographic showing line-drawn people with text: 1.3 billion people living in poverty

working_to_end_the_pandemic_for_people_all_over_the_world_03.svg

Because we know that it is not just vaccines that will help bring an end to this pandemic, but vaccinations, we are working closely with global health partners to provide expertise and resources that strengthen healthcare systems where greater support may be needed and support country efforts to deliver and administer vaccines to remote and underserved populations.

We have expanded our partnership with drone delivery service Zipline, Inc. to distribute vaccines requiring cold chain, including our COVID-19 vaccine to some of the most remote areas of Africa. In Ghana, a country where around 40 percent of the population lives in rural areas, Zipline’s drones will bring doses to many of these areas. Zipline plans to replicate this novel delivery model in other countries, moving next to Nigeria where there are similar challenges reaching remote regions.

Looking ahead to the potential introduction of our COVID-19 oral treatment candidate, Pfizer is focused on strategies to help ensure that this novel treatment, if authorized or approved, can reach those most in need. In November 2021, Pfizer and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income countries, announced the signing of a voluntary license agreement for Pfizer’s COVID-19 oral treatment. MPP will grant sub-licenses to qualified generic medicine manufacturers to facilitate additional production and distribution of the treatment to up to approximately 53 percent of the population living in in low- and lower-middle-income countries as well as some upper-middle-income countries with a disproportionate number of people living in poverty.

COVID-19 vaccine delivered outside of rural Health Center in Ghana

large_working_to_end_the_pandemic_for_people_all_over_the_world_04.jpg

medium_working_to_end_the_pandemic_for_people_all_over_the_world_04.jpg

small_working_to_end_the_pandemic_for_people_all_over_the_world_04.jpg

thumbnail_working_to_end_the_pandemic_for_people_all_over_the_world_04.jpg

working_to_end_the_pandemic_for_people_all_over_the_world_04.jpg

Partnering to Improve Cancer Care in Low- and Middle-Income Countries

Male healthcare worker adjusting IV pole in hospital setting

partnering_to_improve_cancer_care_in_low_and_middle_income_countries_hero.jpeg

Expanding COVID-19 Manufacturing Efforts to Increase Global Vaccine Access

Two Pfizer colleagues prepare vaccine shipment

expanding_covid_19_manufacturing_efforts_to_increase_global_vaccine_access_hero.png

thumbnail_Image 1_Mona Babury.jpg

Building on our reputation as a leader in diversity, equity, and inclusion (DEI), we updated our DEI strategy in 2021 to embed these principles into our workplace and further advance one of our five Bold Moves, unleash the power of our people.

Our updated strategy embraces the vision to be a best-in-class organization that embeds DEI in our workplace and into our purpose of delivering breakthroughs that change patients’ lives, and includes a new governance model. By having a clear overarching DEI vision, we’re able to outline distinct DEI roles and accountabilities, align our therapeutic areas and divisions with our vision, and assess our progress against measurable outcomes. As our Chief Diversity, Equity and Inclusion Officer Ramcess Jean-Louis said, “We approach DEI with the same Pfizer discipline applied to everything else we do – what gets measured, gets improved. Pfizer’s DEI strategy is built around tangible efforts that can be measured against three key stakeholder pillars.”

These three pillars support our core value of Equity, ensuring every person is seen, heard, and cared for. The pillars include building a more inclusive colleague experience, advancing equitable health outcomes, and transforming society with external DEI partnerships – creating a strong foundation from which to develop an inclusive workplace for all.

From supplier diversity to equitable accessibility planning for product launches, we considered all aspects of our business and identified ways to embed DEI, remove barriers, and build our inclusive culture. 

Our new strategy came to life in 2021 through our first global safe space listening session and launch of our Breakthrough Fellowship Program. The global safe space listening session was in response to the Afghanistan withdrawal and offered colleagues, especially those who identify as refugees or veterans, an opportunity to share their feelings around the news. Safe space listening conversations will continue to be planned based on world events.

Understanding that minority communities are underrepresented in leadership across corporate America, the Breakthrough Fellowship Program is a nine-year commitment to increase minority representation at Pfizer. It’s a first-of-its-kind fellowship program focused on advancing undergraduate students and fellows of Black/African American, Latino Community/Hispanic and Native American descent with the goal of engaging 100 Fellows by 2025.

Learn more about our diversity and belonging efforts, inclusive research, and partnerships in the Social section of this year’s [ESG Report](/esg/).

large_ensuring_broad_and_affordable_access_to_paxlovid_hero.jpeg

medium_ensuring_broad_and_affordable_access_to_paxlovid_hero.jpeg

small_ensuring_broad_and_affordable_access_to_paxlovid_hero.jpeg

thumbnail_ensuring_broad_and_affordable_access_to_paxlovid_hero.jpeg

ensuring_broad_and_affordable_access_to_paxlovid_hero.jpeg

Ensuring Broad and Affordable Access to Paxlovid™

Pfizer is committed to working toward equitable access to Paxlovid for all people, aiming to deliver this therapeutic as soon as possible, once authorized or approved, and at an affordable price. During the pandemic, Pfizer will offer its oral therapy through a tiered pricing approach, pending country authorization or approval, based on the income level of each country to promote equity of access across the globe. High and upper-middle income countries will pay more than lower income countries, which will pay a not-for-profit price.

large_new_Ensuring-Broad-and-Affordable_inline.jpg

medium_new_Ensuring-Broad-and-Affordable_inline.jpg

small_new_Ensuring-Broad-and-Affordable_inline.jpg

thumbnail_new_Ensuring-Broad-and-Affordable_inline.jpg

ensuring_broad_and_affordable_access_to_paxlovid_01.jpg

Pfizer continues to invest to support the manufacturing and distribution of Paxlovid, including exploring potential contract manufacturing options. Pfizer has raised its production projections from 80 million to up to 120 million courses of treatment by the end of 2022, depending on the global need.

The company has entered into agreements with multiple countries and has initiated bilateral outreach to more than 100 countries around the world. Additionally, Pfizer has signed a voluntary license agreement with the Medicines Patent Pool (MPP) for its oral treatment to help expand access, pending country regulatory authorization or approval, in 95 low- and middle-income countries that account for approximately 53% of the world’s population.

*Paxlovid™ has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg (88 lbs)) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.*

*The emergency use of Paxlovid™ is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.*

Pfizer scientists looking into a microscope

large_broadening_access_to_the_covid_19_vaccine_01.jpg

medium_broadening_access_to_the_covid_19_vaccine_01.jpg

small_broadening_access_to_the_covid_19_vaccine_01.jpg

thumbnail_broadening_access_to_the_covid_19_vaccine_01.jpg

broadening_access_to_the_covid_19_vaccine_hero.jpg

Broadening Access to the COVID-19 Vaccine

2020 was a year we will never forget. While we were met with incredible suffering and loss, there were also many examples of courage, hope and pride. We couldn’t think of a better example of all three than when we, in partnership with BioNTech, received the first authorizations for our COVID-19 vaccine in individuals 16 years of age and older at the end of 2020.

Since then, we’ve continued to follow the science, working around the clock to broaden individual access to the vaccine. Through these efforts, we were able to do the following in many countries around the world in 2021:*^1,2*

- Expand regulatory authorizations of the vaccine to include individuals 12 through 15, and then 5 through 11, years of age
- Receive authorizations for third shots for those immunocompromised and also booster doses for adults 16 years and older in the U.S. (now authorized for 12 and older as of January 2022) and 18 years and older in the European Union, with other authorizations varying by country

Further, we continue to explore effectiveness and safety of the Pfizer-BioNTech COVID-19 vaccine in ages 2 to 5 years.

We are incredibly proud of all we were able to accomplish in 2021, but the work is not over. We are continuing to work on ongoing COVID-19 trials, including studying and monitoring the emergence of new variants, so that we can always stay vigilant as we fight the virus.*^3*

Pfizer scientists reads letter from thankful first-grade students

large_broadening_access_to_the_covid_19_vaccine_02.png

medium_broadening_access_to_the_covid_19_vaccine_02.png

small_broadening_access_to_the_covid_19_vaccine_02.png

thumbnail_broadening_access_to_the_covid_19_vaccine_02.png

broadening_access_to_the_covid_19_vaccine_02.png

We are also dedicated to helping ensure low- and middle-income countries receive vaccines and have committed to distributing 2 billion doses by the end of 2022. We are working with governments, health institutions and non-profit organizations to distribute the vaccine equitably. For us, the question is not who should get the vaccine, but what do we need to do so that countries globally can have access to it.

*Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at [www.cvdvaccine-us.com](https://www.cvdvaccine-us.com).*

large_our_global_patients_in_focus_week_01.jpg

medium_our_global_patients_in_focus_week_01.jpg

small_our_global_patients_in_focus_week_01.jpg

thumbnail_our_global_patients_in_focus_week_01.jpg

At Pfizer, we are committed to ensuring that the perspectives of patients are not only taken into consideration but embedded into every facet of our work to help people live longer, healthier lives. Our purpose is focused squarely on breakthroughs that change patients’ lives. From research and development to product access, we work hand in hand with patients, caregivers and patient advocacy groups, to meet their needs.

This year, we hosted our first ever global Patients in Focus, a week-long activation of our focus on the patient perspective. Under the theme “Patients are Our Why,” regional leaders from across the enterprise hosted more than 60 events designed to share patient and caregiver stories that build our understanding of the needs of all patients, bring colleagues together to discuss patient-centric design, and showcase impactful patient advocacy efforts across the company. Over 38,000 colleagues and 340 patient advocacy groups participated in Patients in Focus.

Graphic of text reading 60 global and local events hosted, 25 countries represented, and 38,000 Pfizer colleagues attended

our_global_patients_in_focus_week_01.svg

From patient award ceremonies to patient storytelling initiatives and patient-focused mini-magazines, the week served as an opportunity to honor and celebrate the patient partners we work with year-round. Internally, the week also allowed colleagues to highlight best practices for engaging patients. For example, the Global Patient Advocacy Team hosted several live global symposia featuring patient advocacy leaders from across the organization, sharing their tips for successful patient-focused initiatives. The symposia also highlighted our coordination guidelines for engaging with patients and patient advocacy groups, designed to help colleagues align on shared priorities, activities, and funding, and enhance both the relationship with and the value we bring to our partners.

In a live fireside chat with more than 200 patient advocacy groups and CEO Albert Bourla, Chief Medical Officer, Aida Habtezion shared the importance of delivering breakthroughs to all patients, regardless of their circumstances. Albert reiterated the need to strive for respectful, equitable, impactful, bidirectional, and culturally appropriate interactions with patients and patient advocacy organizations. “This is possible only when everyone at Pfizer recognizes the importance of patient advocacy and actively works to include patient voices, insights, and experiences in every facet of our work,” he said.

2021 Stories